B. Riley Securities Reiterates Buy Rating on NUTX
B. Riley Securities reiterated its buy rating on NUTX with a $290 price target, a 79.37% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating on NUTX on June 26, 2026, setting a $290 price target.
- B. Riley Securities's $290 price target implies 79.37% upside from Nutex Health Inc.'s ($NUTX) current $161.68 share price.
- Shares of NUTX traded near $161.68 on Friday, reflecting analysts' ongoing positive outlook.
- Recent insider buying activity includes CEO Thomas Vo purchasing 75,747 shares on May 28, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities reiterated its buy rating on NUTX on June 26, 2026, maintaining a price target of $290. This reflects continued confidence in the company's potential.
B. Riley Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in NUTX
Several institutional investors have adjusted their positions in NUTX. BlackRock, Inc. grew its holdings by 97,802 shares, ending with 379,355 shares valued at about $36.1 million, a 34.7% increase. Pertento Partners LLP added 49,548 shares, bringing its total to 373,970 shares worth $35.5 million, marking a 15.3% rise. Vanguard Capital Management LLC opened a new position with 219,131 shares, valued at approximately $20.8 million. American Century Companies Inc increased its stake by 71,409 shares to 203,450 shares, valued at $19.3 million, a 54.1% increase. Meanwhile, Topline Capital Management, LLC reduced its holdings by 497,694 shares, leaving it with 177,800 shares worth $16.9 million, a 73.7% decrease.
Nutex Health Inc. Stock Down 14.6%
Shares of NUTX traded near $161.68 on Friday. The stock has experienced significant institutional interest, reflecting a positive outlook from major funds. The company's stock performance is closely watched by investors, given the recent analyst ratings and insider activities.
$NUTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Nutex Health Inc.
Recent insider activity at NUTX includes several purchases. On May 28, 2026, CEO Thomas Vo acquired 75,747 shares. Earlier, on April 23, 2026, insiders including Cheryl Yvonne Grenas, Frank Jaumot, Michael Lee Reed, and Scott Saunders each bought 823 shares. Kelvin Spears also purchased 2,519 shares on June 4, 2026. These transactions suggest confidence from those within the company.
Analysts Set New Price Targets
On June 26, 2026, B. Riley Securities reiterated its buy rating on NUTX with a price target of $290. Earlier in June, Lake Street initiated coverage with a buy rating and a $235 target. Maxim Group maintained its buy rating multiple times throughout 2025, with targets ranging from $75 to $225. The consensus among analysts remains optimistic, with a strong buy recommendation and a mean target price reflecting expected growth.
Bottom Line
The reiteration of the buy rating by B. Riley Securities, along with significant institutional activity and insider buying, highlights the market's positive sentiment towards NUTX. Investors closely monitor these updates, understanding that 13F filings and analyst ratings are historical and may not reflect current positions. Nevertheless, the data provides valuable insights into the company's perceived potential.
Get Nutex Health Inc. alerts
New 13F filings, insider trades, and analyst moves on $NUTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.